leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12345678910111213...235236»
  • ||||||||||  hydroxychloroquine / Generic mfg., leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    A Rare Case of Discoid Lupus Erythematosus and Consecutive Linear Morphea () -  Feb 21, 2025 - Abstract #AAD2025AAD_3052;    
    Laboratory Data: ANA +1:320. Diagnosis: Overlap syndromes are defined as clinical presentations meeting diagnostic criteria of two different connective tissue diseases, either concurrently or consecutively.(1) In the literature, there are several cases of lupus and scleroderma happening in the same patient, occurring with the systemic presentation of one and the localized form of the other.(2
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
    Journal:  Fatal Neutropenia Sepsis Following Acute Methotrexate Toxicity. (Pubmed Central) -  Feb 21, 2025   
    By day 7, his blood counts and symptoms improved, and he was discharged on day 12. This case underscores the importance of patient education on proper MTX dosing to prevent life-threatening complications, particularly in high-risk populations such as the elderly and those with CKD.
  • ||||||||||  botensilimab (AGEN1181) / Agenus
    Enrollment closed, Trial completion date, Trial primary completion date:  A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Feb 18, 2025   
    P2,  N=81, Active, not recruiting, 
    Trial completion date: Nov 2024 --> Jul 2025 Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, Asparlas (calaspargase pegol-mknl) / Servier, Takeda, Leadiant Biosci
    Trial completion date, Trial primary completion date, Pan tumor:  Venetoclax Basket Trial for High Risk Hematologic Malignancies (clinicaltrials.gov) -  Feb 18, 2025   
    P1,  N=92, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial completion date: Apr 2027 --> Jul 2028 | Trial primary completion date: Apr 2025 --> Jul 2026
  • ||||||||||  Journal:  Efficacy of Neoadjuvant Short-Course Radiation Therapy Followed by Oxaliplatin-Based Chemotherapy for Locally Advanced Rectal Adenocarcinoma: A Single-Center Experience From Saudi Arabia. (Pubmed Central) -  Feb 18, 2025   
    Background The 5-fluorouracil (5-FU), capecitabine-based long-course or short-course radiotherapy (SCRT) eventually preceded or followed by induction or consolidation chemotherapy (CT) and resection represents the preferred regimen for the treatment of locally advanced rectal cancer (LARC)...All participants underwent short-term radiotherapy (25 Grays (Gy) over fractions within one week) followed by CT with 5-FU, leucovorin, and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (CAPOX), constituting the total neoadjuvant therapy (TNT)...These insights could refine patient selection for TNT and inform future strategies to optimize treatment outcomes in rectal cancer. Prospective multicenter studies are warranted.
  • ||||||||||  paclitaxel / Generic mfg.
    Journal:  The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarcinoma therapy. (Pubmed Central) -  Feb 17, 2025   
    Thus, the combined effect of N6L with either gemcitabine, FOLFOX and paclitaxel (PTX) on the survival of PANC-1, Mia-PaCa-2 and BxPC3 was studied and shown additive effect...We have then combined the advantageous features of both porous and negatively charged surfaces of calcium carbonate (CaCO3) particles and host molecules CD for developing carrier enabling all at once the loading of PTX (hydrophobic drug) and N6L (cationic drug). This association generates water-soluble particles capable of targeting via N6L and delivering paclitaxel to tumor cells.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Review, Journal, IO biomarker:  Beyond Chemotherapy: Exploring 5-FU Resistance and Stemness in Colorectal Cancer. (Pubmed Central) -  Feb 17, 2025   
    The efficacy of 5-FU is enhanced by combination therapies such as FOLFOXIRI and targeted treatments like bevacizumab, cetuximab, and panitumumab, particularly in KRAS wild-type tumors, despite associated toxicity...Advances in immunotherapy, including immune checkpoint inhibitors and cancer vaccines, along with nanomedicine-based therapies, offer promising targeted drug delivery systems that enhance specificity, reduce toxicity, and provide novel approaches for overcoming resistance mechanisms. Integrating these innovative strategies with traditional therapies may enhance the effectiveness of CRC therapy by addressing the underlying causes of 5-FU resistance in CSCs.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Journal:  Advanced pancreatic cancer treated with camrelizumab combined with apatinib: A case report. (Pubmed Central) -  Feb 17, 2025   
    Immunotherapy and targeted therapy have the potential to increase both the quality of life and survival time of PC patients, particularly those whose tumor progression is not effectively controlled by chemotherapy alone. Nevertheless, further clinical trials are necessary to validate these findings.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Review, Journal, IO biomarker, Metastases:  Narrative review of neoadjuvant therapy in patients with locally advanced colon cancer. (Pubmed Central) -  Feb 14, 2025   
    Integrating these therapies can enhance the surgical and survival outcomes of patients with LACC, highlighting the importance of personalized treatment strategies based on tumor characteristics and response to neoadjuvant interventions. This review discusses the evolving landscape of LACC management, focusing on optimizing treatment approaches for improved patient outcomes.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  FOLFOX regimen induced severe hypokalaemia with hypocalcaemia and hypomagnesaemia. (Pubmed Central) -  Feb 14, 2025   
    Additionally, managing diarrhoea, nausea and vomiting can help minimise potassium loss during chemotherapy. This case describes a patient who developed severe hypokalaemia (1.4?mmol/L) associated with the use of the FOLFOX regimen without any cardiac arrhythmia.
  • ||||||||||  Graspa (eryaspase) / PHAXIAM Therap
    Trial completion:  Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) -  Feb 14, 2025   
    P1,  N=19, Completed, 
    This case describes a patient who developed severe hypokalaemia (1.4?mmol/L) associated with the use of the FOLFOX regimen without any cardiac arrhythmia. Active, not recruiting --> Completed
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  DIRECT: A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer (clinicaltrials.gov) -  Feb 12, 2025   
    P3,  N=528, Active, not recruiting, 
    Trial completion date: Feb 2023 --> Feb 2025 | Recruiting --> Terminated; The study was early closed due to low accrual in August 2022. Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Apr 2025
  • ||||||||||  Trial completion date, Trial primary completion date:  Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer (clinicaltrials.gov) -  Feb 11, 2025   
    P1/2,  N=120, Recruiting, 
    No abstract available Trial completion date: Jan 2025 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Jan 2026
  • ||||||||||  oxaliplatin / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  2 Versus 6 Hour Oxaliplatin Infusions in Patients with Gastrointestinal Cancers (clinicaltrials.gov) -  Feb 5, 2025   
    P2,  N=60, Recruiting, 
    The neuroprotective effects of leucovorin suggest that strategies may be developed that extend the duration of this intervention or adapt it for use in standard risk patients. Active, not recruiting --> Recruiting | Trial completion date: Dec 2024 --> Sep 2026 | Trial primary completion date: Dec 2024 --> Sep 2025
  • ||||||||||  Journal:  Comparative efficacy of cetuximab combined with FOLFOX or CAPEOX in first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer: a multicenter case-control study. (Pubmed Central) -  Feb 4, 2025   
    CAPEOX combined with cetuximab differs from the FOLFOX regimen by using oral capecitabine instead of continuous infusion of fluorouracil, offering greater convenience and cost-effectiveness with higher patient acceptance...The two groups achieved similar median PFS (mPFS) and median OS (mOS), with mPFS of 18 months and 12 months, respectively (P = 0.23), and mOS of 33 months and 20 months, respectively (P = 0.21), with no statistically significant differences. The results of this study demonstrated that CAPEOX combined with cetuximab is an equally viable option for first-line treatment of RAS/BRAF wild-type mCRC as FOLFOX combined with cetuximab.